Human Rabies Vaccines

Rabies

Volumn , Issue , 2007, Pages 505-515

  Briggs, Deborah J ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45849154442     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369366-2/50015-4     Document Type: Chapter

References (41)

1. APCRI Editorial - Present scenerio of anti-rabies vaccination programme in India. Association for the Prevention and Control of Rabies in India Journal 2006, 8:5-7.
2. Arora A., Moeller L., Froeschle J. Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine. Journal of Travel Medicine 2004, 11:195-199.
3. Ayele W., Fekadu M., Zewdie B., et al. Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia. Ethiopian Medical Journal 2001, 39:313-321.
4. Bahmanyar M., Fayaz A., Nour-Salehi S., Mohammadi M., Koprowski H. Successful protection of humans exposed to rabies infection: Post-exposure treatment with the new human diploid cell rabies vaccine and antirabies serum. Journal of the American Medical Association 1976, 236:2751-2754.
5. Barth R., Franke V. Fetal rhesus monkey lung diploid cell vaccine for humans. Laboratory Techniques in Rabies 1996, 297-300. World Health Organization, Geneva. 4th edn. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
6. Barth R., Gruschkau H., Bijok U., et al. A new inactivated tissue culture rabies vaccine for use in man: Evaluation of PCEC vaccine by laboratory tests. Journal of Biological Standards 1984, 12:29-46.
7. Beran J., Honegr K., Banzhoff A., Malerczyk C. Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. Vaccine 2005, 23:3902-3907.
8. Bijok U. Purified chick embryo cell (PCEC) rabies vaccine: A review of the clinical development. Improvements in Rabies Postexposure Treatment 1985, 103-111. Zagreb Institute of Public Health. I. Vodoppija, K.G. Nicholson, S. Smerdel, U. Bijok (Eds.).
9. Bugyaki L., Moons J.H., Blockeel S.R. Survival of the fixed Pasteur virus in Fermi-Semple type phenicated antirabies vaccine and its relation to the degree of immunity conferred. Annales de la Societe belge de medecine tropicale 1959, 39:275-280.
10. Chutivongse S., Wilde H., Supich C., Baer G.M., Fishbein D.B. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 1990, 335:896-898.
11. CBER Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Vaccines and Related Biological Products Advisory Committee Meeting (VRBPAC) November 16, 2005 2005, http://www.fda.gov/cber/advisory/vrbp/vrbpmain.htm.
12. Centers for Disease Control A centennial celebration: Pasteur and the modern era of immunization. Morbidity and Mortality Weekly Report 1985, 34:389-390.
13. Centers for Disease Control Human rabies prevention - United States, 1991. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1991, 40(RR-3):1-14.
14. Centers for Disease Control Human rabies prevention - United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1999, 48(RR-1):1-21.
15. Diaz A.M. Suckling-mouse brain vaccine. Laboratory Techniques in Rabies 1996, 243-250. World Health Organization, Geneva. 4th edn. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
16. Fuenzalida E., Palacios R. Un método mejorado en la preparaciũn de la vacuna antirábica. Bulletin of the Institute of Bacteriology, Chile 1955, 8:3-10.
17. Girard L.S., Fabis M.J., Bastin M., Courtois D., Petiard V., Koprowski H. Expression of a human anti-rabies virus monoclonal antibody in tobacco cell culture. Biochemical And Biophysical Research Communications 2006, 345:602-607.
18. Hanlon C.A., Kuzmin I.V., Blanton J.D., Weldon W.C., Manangan J.S., Rupprecht C.E. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Research 2005, 111:44-54.
19. Harverson G., Wasi C. Use of post-exposure intradermal rabies vaccination in a rural mission hospital. Lancet 1984, 2:313-315.
20. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Experimental Cell Research 1961, 25:585-621.
21. Jones R.L., Froeschle J.E., Atmar R.L., et al. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized double-blind trial with human diploid cell rabies vaccine. Vaccine 2001, 19:4635-4643.
22. Kamoltham T., Singhsa J., Promsaranee U., Sonthon P., Mathean P., Thinyounyong W. Elimination of human rabies in a canine endemic province in Thailand: five-year programme. Bulletin of the World Health Organization 2003, 81:375-381.
23. Lodmell D.L., Ewalt L.C., Parnell M.J., Rupprecht C.E., Hanlon C.A. One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies virus. Vaccine 2006, 23:412-416.
24. Meslin F.-X., Kaplan M.M. General considerations in the production and use of brain-tissue and purified chicken-embryo rabies vaccines for human use. Laboratory Techniques in Rabies 1996, 204-212. World Health Organization, Geneva. 4th edn. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
25. Moore S.M., Ricke T.A., Davis R.D., Briggs D.J. The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. Biologicals 2005, 33:269-276.
26. National Advisory Committee on Immunization Update on rabies vaccines. Canada Communicable Disease Report 2005, 31(ACS-5):1-5. Canada. June 1.
27. Nel L.H. Vaccines for lyssaviruses other than rabies. Expert Review on Vaccines 2005, 4:533-540.
28. Nogueira Y.L. Adverse effect versus quality control of the Fuenzalida-Palacios antirabies vaccine. Revista do Instituto de Medicina Tropical de São Paulo 1998, 40:295-299.
29. Parviz S., Chotani R., McCormick J., Fisher-Hoch, Luby S. Rabies deaths in Pakistan: results of ineffective post-exposure treatment. International Journal of Infectious Diseases 2004, 8:346-352.
30. Plotkin S.A. Rabies vaccine prepared in human cell cultures: progress and perspectives. Review of Infectious Diseases 1980, 2:433-448.
31. Quiambao B.P., Dimaano E.M., Ambas C., Davis R., Banzhoff A., Malerczyk C. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005, 23:1709-1714.
32. Quiambao B.P., Lang J., Vital S., et al. Economic issues in postexposure rabies treatment. Journal of Travel Medicine 2000, 6:238-242.
33. WHO World Health Organization Expert Committee on Rabies. Sixth report. WHO Technical Report Series No 523, Geneva, WHO 1973.
34. WHO World Health Organization position paper on rabies vaccines. Weekly Epidemiological Record 2002, 77:109-119.
35. WHO World Health Organization. Meeting report: Discussion on WHO requirements for rabies vaccine for human use: potency assay 2003, WHO, Geneva.
36. WHO World Health Organization. WHO Expert Consultation on Rabies. First Report. WHO Technical Report Series No 931 2005, 121. WHO, Geneva.
37. WHO New guidelines and recommendations established by the ECBS, 56th meeting 2006, 55. WHO/BS/05.2015, WHO, Geneva.
38. Wiktor T.J., Fernandes M.V., Koprowski H. Cultivation of rabies virus in human diploid cell strain WI-38. Journal of Immunology 1964, 93:353-360.
39. Wiktor T.J., Sokol F., Kuwert E., Koprowski H. Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proceedings of the Society for Experimental Biology and Medicine 1969, 131:799-805.
40. Wilde H., Tipkong P., Kwahplod K. Economic issues in postexposure rabies treatment. Journal of Travel Medicine 1999, 6:238-242.
41. Yusibov V., Hooper D.C., Spitsin S.V., et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 2002, 19:3155-3164.